Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency

Richard L Wasserman, Joseph A Church, Mark Stein, James Moy, Martha White, Steven Strausbaugh, Harry Schroeder, Mark Ballow, James Harris, Isaac Melamed, David Elkayam, William Lumry, Daniel Suez, Syed M Rehman, Richard L Wasserman, Joseph A Church, Mark Stein, James Moy, Martha White, Steven Strausbaugh, Harry Schroeder, Mark Ballow, James Harris, Isaac Melamed, David Elkayam, William Lumry, Daniel Suez, Syed M Rehman

Abstract

Introduction: An investigational 10% liquid intravenous immunoglobulin (IVIG) was studied in 63 patients with primary immunodeficiency (PID) at 15 study sites.

Methods: Patients were treated every 3 or 4 weeks with 254-1029 mg/kg/infusion of IVIG.

Results: Overall, Biotest-IVIG infusions were well tolerated. The proportion of infusions that were associated with adverse events during infusion, and up to 72 h after infusion, including those unrelated to study product, was 27.7% with an upper 95% confidence limit ≤30.6%. Two serious bacterial infections (SBIs) were observed resulting in a serious bacterial infection rate of 0.035 per person per year and an upper one-sided 99% confidence limit of ≤0.136 SBI/patient/year. The number of days of work or school missed due to infection were relatively low at 2.28 days/patient/year. Two patients were hospitalized for infection producing a rate of 0.21 hospitalization days/patient/year. The IgG half-life was approximately 30 days with variation among individuals.

Conclusions: Pharmacokinetic parameters of specific antibody activities were essentially the same as those of total IgG. Biotest-IVIG is safe and effective in the treatment of PID.

References

    1. Bruton OC. Agammaglobulinema. Pediatrics. 1952;9:722–727.
    1. Cohn EJ, Strong LE, Hughes WL, Jr, et al. Preparation and properties of serum and plasma proteins III: A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 1946;68:459–475. doi: 10.1021/ja01207a034.
    1. Melin JL, Oncley M, Richert DA, et al. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta-lipoprotein into subfractions of human plasma. J Am Chem Soc. 1949;71:541–550. doi: 10.1021/ja01170a048.
    1. Wells MA, Wittek AE, Epstein JS, Marcus-Sekura C, Daniel S, Tankersley DL, et al. Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma. Transfusion. 1986;6:210–213. doi: 10.1046/j.1537-2995.1986.26286152919.x.
    1. Mitra G, Wong MF, Mozen MM, McDougal JS, Levy JA. Elimination of infectious retroviruses during preparation of immunoglobulins. Transfusion. 1986;26:394–397. doi: 10.1046/j.1537-2995.1986.26486262753.x.
    1. Yei S, Yu MW, Tankersley DL. Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion. 1992;32:824–828. doi: 10.1046/j.1537-2995.1992.32993110753.x.
    1. Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivatives I: Disruption of lipid-enveloped viruses by tri (n-butyl) phosphate detergent combinations. Transfusion. 1985;25:516–522. doi: 10.1046/j.1537-2995.1985.25686071422.x.
    1. Omar A, Kempf C. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration. Transfusion. 2002;42:1005–1010. doi: 10.1046/j.1537-2995.2002.00145.x.
    1. FDA/CBER. Guidance for industry: Safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (Human) as replacement therapy for primary humoral immunodeficiency, , June 2008.
    1. Ochs HD, Pinciaro PJ, et al. Octagam® 5%, an Intravenous IgG Product, is efficacious and well tolerated in patients with primary immunodeficiency diseases. J Clin Immunol. 2004;24(3):309–314. doi: 10.1023/B:JOCI.0000025453.23817.3f.
    1. Berger M, Pinciaro PJ, et al. Safety, efficacy and pharmacokinetics of flebogamma® 5% [Immune Globulin Intravenous (Human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol. 2004;24(4):389–396. doi: 10.1023/B:JOCI.0000029108.18995.61.
    1. Berger M, et al. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma® 5% DIF, the next generation of Flebogamma. J Clin Immunol. 2007;27:628–633. doi: 10.1007/s10875-007-9107-x.
    1. Church JA, Leibl H, Stein MR, Melamed IR, Rubinstein A, Schneider LC, et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin (IGIV 10%) in patients with primary immunodeficiency. J Clin Immunol. 2006;26:388–395. doi: 10.1007/s10875-006-9025-3.
    1. Stein MR, Nelson RP, Church JA, Wasserman RL, Church JA, Wasserman RL, et al. Safety and efficacy of Privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29:137–144. doi: 10.1007/s10875-008-9231-2.
    1. Berger M, Pinciaro PJ, Althaus A, Ballow M, Chouksey A, Moy J, et al. Efficacy, pharmacokinetics, safety, and tolerability of flebogamma® 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. J Clin Immunol. 2010;30:321–329. doi: 10.1007/s10875-009-9348-y.
    1. Schiff RI. Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action. Pediatr Allergy Immunol. 1994;5:63–87. doi: 10.1111/j.1399-3038.1994.tb00222.x.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅